0	16	Characterization	characterization	NN
17	19	of	of	IN
20	21	a	a	DT
22	28	mutant	mutant	JJ
29	33	cell	cell	NN
34	38	line	line	NN
39	43	that	that	WDT
44	48	does	do	VBZ
49	52	not	not	RB
53	61	activate	activate	VB
62	71	NF-kappaB	nf-kappab	NN
72	74	in	in	IN
75	83	response	response	NN
84	86	to	to	TO
87	95	multiple	multiple	JJ
96	103	stimuli	stimulus	NNS
103	104	.	.	.

106	114	Numerous	numerous	JJ
115	120	genes	gene	NNS
121	129	required	require	VBN
130	136	during	during	IN
137	140	the	the	DT
141	147	immune	immune	JJ
148	150	or	or	CC
151	163	inflammation	inflammation	NN
164	172	response	response	NN
173	175	as	as	RB
176	180	well	well	RB
181	183	as	as	IN
184	187	the	the	DT
188	196	adhesion	adhesion	NN
197	204	process	process	NN
205	208	are	be	VBP
209	218	regulated	regulate	VBN
219	221	by	by	IN
222	229	nuclear	nuclear	JJ
230	236	factor	factor	NN
237	243	kappaB	kappaB	NNP
244	245	(	(	(
245	254	NF-kappaB	NF-kappaB	NNP
254	255	)	)	)
255	256	.	.	.

257	267	Associated	associate	VBN
268	272	with	with	IN
273	276	its	its	PRP$
277	286	inhibitor	inhibitor	NN
286	287	,	,	,
288	289	I	i	NN
290	296	kappaB	kappaB	NNP
296	297	,	,	,
298	307	NF-kappaB	NF-kappaB	NNP
308	315	resides	reside	VBZ
316	318	as	as	IN
319	321	an	an	DT
322	330	inactive	inactive	JJ
331	335	form	form	NN
336	338	in	in	IN
339	342	the	the	DT
343	352	cytoplasm	cytoplasm	NN
352	353	.	.	.

354	358	Upon	upon	IN
359	370	stimulation	stimulation	NN
371	373	by	by	IN
374	381	various	various	JJ
382	388	agents	agent	NNS
388	389	,	,	,
390	391	I	i	NN
392	398	kappaB	kappaB	NNP
399	401	is	be	VBZ
402	413	proteolyzed	proteolyze	VBN
414	417	and	and	CC
418	427	NF-kappaB	NF-kappaB	NNP
428	440	translocates	translocate	VBZ
441	443	to	to	TO
444	447	the	the	DT
448	455	nucleus	nucleus	NN
455	456	,	,	,
457	462	where	where	WRB
463	465	it	it	PRP
466	475	activates	activate	VBZ
476	479	its	its	PRP$
480	486	target	target	NN
487	492	genes	gene	NNS
492	493	.	.	.

494	497	The	the	DT
498	510	transduction	transduction	NN
511	519	pathways	pathway	NNS
520	524	that	that	WDT
525	529	lead	lead	VBP
530	532	to	to	TO
533	534	I	i	NN
535	541	kappaB	kappab	NN
542	554	inactivation	inactivation	NN
555	561	remain	remain	VBP
562	568	poorly	poorly	RB
569	579	understood	understand	VBN
579	580	.	.	.

581	583	In	in	IN
584	588	this	this	DT
589	594	study	study	NN
594	595	,	,	,
596	598	we	we	PRP
599	603	have	have	VBP
604	617	characterized	characterize	VBN
618	619	a	a	DT
620	628	cellular	cellular	JJ
629	635	mutant	mutant	NN
635	636	,	,	,
637	640	the	the	DT
641	654	70/Z3-derived	70/z3-derived	JJ
655	660	1.3E2	1.3e2	NN
661	667	murine	murine	JJ
668	673	pre-B	pre-b	JJ
674	678	cell	cell	NN
679	683	line	line	NN
683	684	,	,	,
685	689	that	that	WDT
690	694	does	do	VBZ
695	698	not	not	RB
699	707	activate	activate	VB
708	717	NF-kappaB	nf-kappab	NN
718	720	in	in	IN
721	729	response	response	NN
730	732	to	to	TO
733	740	several	several	JJ
741	748	stimuli	stimulus	NNS
748	749	.	.	.

750	752	We	we	PRP
753	764	demonstrate	demonstrate	VBP
765	769	that	that	IN
770	774	upon	upon	IN
775	786	stimulation	stimulation	NN
787	789	by	by	IN
790	808	lipopolysaccharide	lipopolysaccharide	NN
808	809	,	,	,
810	815	Taxol	Taxol	NNP
815	816	,	,	,
817	824	phorbol	phorbol	NN
825	834	myristate	myristate	NN
835	842	acetate	acetate	NN
842	843	,	,	,
844	857	interleukin-1	interleukin-1	NN
857	858	,	,	,
859	861	or	or	CC
862	877	double-stranded	double-stranded	JJ
878	881	RNA	RNA	NNP
881	882	,	,	,
883	884	I	i	NN
885	891	kappaB	kappab	NN
892	897	alpha	alpha	NN
898	900	is	be	VBZ
901	904	not	not	RB
905	913	degraded	degrade	VBN
913	914	,	,	,
915	917	as	as	IN
918	919	a	a	DT
920	926	result	result	NN
927	929	of	of	IN
930	932	an	an	DT
933	940	absence	absence	NN
941	943	of	of	IN
944	951	induced	induce	VBN
952	967	phosphorylation	phosphorylation	NN
968	970	on	on	IN
971	978	serines	serine	NNS
979	981	32	32	CD
982	985	and	and	CC
986	988	36	36	CD
988	989	.	.	.

990	997	Neither	neither	CC
998	999	a	a	DT
1000	1008	mutation	mutation	NN
1009	1011	in	in	IN
1012	1013	I	i	NN
1014	1020	kappaB	kappab	NN
1021	1026	alpha	alpha	NN
1027	1030	nor	nor	CC
1031	1032	a	a	DT
1033	1041	mutation	mutation	NN
1042	1044	in	in	IN
1045	1048	p50	p50	NN
1049	1051	or	or	CC
1052	1056	relA	relA	NNP
1056	1057	,	,	,
1058	1061	the	the	DT
1062	1065	two	two	CD
1066	1071	major	major	JJ
1072	1080	subunits	subunit	NNS
1081	1083	of	of	IN
1084	1093	NF-kappaB	NF-kappaB	NNP
1094	1096	in	in	IN
1097	1101	this	this	DT
1102	1106	cell	cell	NN
1107	1111	line	line	NN
1111	1112	,	,	,
1113	1121	accounts	account	VBZ
1122	1125	for	for	IN
1126	1130	this	this	DT
1131	1146	phosphorylation	phosphorylation	NN
1147	1153	defect	defect	NN
1153	1154	.	.	.

1155	1157	As	as	RB
1158	1162	well	well	RB
1163	1165	as	as	IN
1166	1177	culminating	culminate	VBG
1178	1180	in	in	IN
1181	1184	the	the	DT
1185	1194	inducible	inducible	JJ
1195	1210	phosphorylation	phosphorylation	NN
1211	1213	of	of	IN
1214	1215	I	i	NN
1216	1222	kappaB	kappab	NN
1223	1228	alpha	alpha	NN
1229	1231	on	on	IN
1232	1239	serines	serine	NNS
1240	1242	32	32	CD
1243	1246	and	and	CC
1247	1249	36	36	CD
1249	1250	,	,	,
1251	1254	all	all	PDT
1255	1258	the	the	DT
1259	1266	stimuli	stimulus	NNS
1267	1271	that	that	WDT
1272	1275	are	be	VBP
1276	1284	inactive	inactive	JJ
1285	1287	on	on	IN
1288	1293	1.3E2	1.3e2	NN
1294	1299	cells	cell	NNS
1300	1307	exhibit	exhibit	VBP
1308	1309	a	a	DT
1310	1321	sensitivity	sensitivity	NN
1322	1324	to	to	TO
1325	1328	the	the	DT
1329	1340	antioxidant	antioxidant	JJ
1341	1352	pyrrolidine	pyrrolidine	NN
1353	1368	dithiocarbamate	dithiocarbamate	NN
1369	1370	(	(	(
1370	1374	PDTC	PDTC	NNP
1374	1375	)	)	)
1375	1376	.	.	.

1377	1379	In	in	IN
1380	1388	contrast	contrast	NN
1388	1389	,	,	,
1390	1397	stimuli	stimulus	NNS
1398	1402	such	such	JJ
1403	1405	as	as	IN
1406	1418	hyperosmotic	hyperosmotic	JJ
1419	1424	shock	shock	NN
1425	1427	or	or	CC
1428	1439	phosphatase	phosphatase	NN
1440	1450	inhibitors	inhibitor	NNS
1450	1451	,	,	,
1452	1457	which	which	WDT
1458	1461	use	use	VBP
1462	1478	PDTC-insensitive	pdtc-insensitive	JJ
1479	1487	pathways	pathway	NNS
1487	1488	,	,	,
1489	1495	induce	induce	VBP
1496	1497	I	i	NN
1498	1504	kappaB	kappab	NN
1505	1510	alpha	alpha	NN
1511	1522	degradation	degradation	NN
1523	1525	in	in	IN
1526	1531	1.3E2	1.3e2	NN
1531	1532	.	.	.

1533	1541	Analysis	Analysis	NNP
1542	1544	of	of	IN
1545	1548	the	the	DT
1549	1554	redox	redox	NN
1555	1561	status	status	NN
1562	1564	of	of	IN
1565	1570	1.3E2	1.3e2	NN
1571	1575	does	do	VBZ
1576	1579	not	not	RB
1580	1586	reveal	reveal	VB
1587	1590	any	any	DT
1591	1601	difference	difference	NN
1602	1606	from	from	IN
1607	1616	wild-type	wild-type	JJ
1617	1622	70Z/3	70z/3	NN
1622	1623	.	.	.

1624	1626	We	we	PRP
1627	1631	also	also	RB
1632	1638	report	report	VBP
1639	1643	that	that	IN
1644	1647	the	the	DT
1648	1653	human	human	JJ
1654	1660	T-cell	t-cell	NN
1661	1669	leukemia	leukemia	NN
1670	1675	virus	virus	NN
1676	1680	type	type	NN
1681	1682	1	1	CD
1683	1684	(	(	(
1684	1699	HTLV-1)-derived	htlv-1)-derived	JJ
1700	1703	Tax	Tax	NNP
1704	1719	trans-activator	trans-activator	NN
1720	1727	induces	induce	VBZ
1728	1737	NF-kappaB	NF-kappaB	NNP
1738	1746	activity	activity	NN
1747	1749	in	in	IN
1750	1755	1.3E2	1.3e2	NN
1755	1756	,	,	,
1757	1767	suggesting	suggest	VBG
1768	1772	that	that	IN
1773	1777	this	this	DT
1778	1783	viral	viral	JJ
1784	1791	protein	protein	NN
1792	1796	does	do	VBZ
1797	1800	not	not	RB
1801	1808	operate	operate	VB
1809	1812	via	via	IN
1813	1816	the	the	DT
1817	1826	defective	defective	JJ
1827	1834	pathway	pathway	NN
1834	1835	.	.	.

1836	1843	Finally	finally	RB
1843	1844	,	,	,
1845	1847	we	we	PRP
1848	1852	show	show	VBP
1853	1857	that	that	IN
1858	1861	two	two	CD
1862	1867	other	other	JJ
1868	1869	I	i	NN
1870	1876	kappaB	kappab	NN
1877	1886	molecules	molecule	NNS
1886	1887	,	,	,
1888	1889	I	i	NN
1890	1896	kappaB	kappab	NN
1897	1901	beta	beta	NN
1902	1905	and	and	CC
1906	1909	the	the	DT
1910	1918	recently	recently	RB
1919	1929	identified	identify	VBN
1930	1931	I	i	NN
1932	1938	kappaB	kappab	NN
1939	1946	epsilon	epsilon	NN
1946	1947	,	,	,
1948	1951	are	be	VBP
1952	1955	not	not	RB
1956	1964	degraded	degrade	VBN
1965	1967	in	in	IN
1968	1971	the	the	DT
1972	1977	1.3E2	1.3e2	NN
1978	1982	cell	cell	NN
1983	1987	line	line	NN
1988	1997	following	follow	VBG
1998	2009	stimulation	stimulation	NN
2009	2010	.	.	.

2011	2014	Our	our	PRP$
2015	2022	results	result	NNS
2023	2034	demonstrate	demonstrate	VBP
2035	2039	that	that	IN
2040	2045	1.3E2	1.3e2	NN
2046	2048	is	be	VBZ
2049	2050	a	a	DT
2051	2059	cellular	cellular	JJ
2060	2072	transduction	transduction	NN
2073	2079	mutant	mutant	NN
2080	2090	exhibiting	exhibit	VBG
2091	2092	a	a	DT
2093	2099	defect	defect	NN
2100	2102	in	in	IN
2103	2104	a	a	DT
2105	2109	step	step	NN
2110	2114	that	that	WDT
2115	2117	is	be	VBZ
2118	2126	required	require	VBN
2127	2129	by	by	IN
2130	2137	several	several	JJ
2138	2147	different	different	JJ
2148	2155	stimuli	stimulus	NNS
2156	2158	to	to	TO
2159	2167	activate	activate	VB
2168	2177	NF-kappaB	NF-kappaB	NNP
2177	2178	.	.	.

2179	2181	In	in	IN
2182	2190	addition	addition	NN
2190	2191	,	,	,
2192	2196	this	this	DT
2197	2205	analysis	analysis	NN
2206	2214	suggests	suggest	VBZ
2215	2216	a	a	DT
2217	2223	common	common	JJ
2224	2228	step	step	NN
2229	2231	in	in	IN
2232	2235	the	the	DT
2236	2245	signaling	signaling	NN
2246	2254	pathways	pathway	NNS
2255	2259	that	that	WDT
2260	2267	trigger	trigger	VBP
2268	2269	I	i	NN
2270	2276	kappaB	kappab	NN
2277	2282	alpha	alpha	NN
2282	2283	,	,	,
2284	2285	I	i	NN
2286	2292	kappaB	kappab	NN
2293	2297	beta	beta	NN
2297	2298	,	,	,
2299	2302	and	and	CC
2303	2304	I	i	NN
2305	2311	kappaB	kappab	NN
2312	2319	epsilon	epsilon	NN
2320	2331	degradation	degradation	NN
2331	2332	.	.	.